International Trade Department - Liu Xinyi

In July 2025, the global pharmaceutical industry event CPHI Southeast Asia was grandly held in Kuala Lumpur, Malaysia. As the most influential exhibition for pharmaceutical raw materials and pharmaceutical technology in Southeast Asia, CPHI Southeast Asia brings together global pharmaceutical enterprises, industry experts and high-quality buyers, building an efficient platform for trade and cooperation. Sichuan Xieli Pharmaceutical Co., Ltd. participated in the exhibition with its core API products, becoming the focus of the exhibition with its patented extraction technology, international certification qualifications and innovative cooperation models, further deepening the company's strategic layout in the Southeast Asian market.

Star Products Attract Attention, Demonstrating Strong Technical Strength

The exhibition focused on displaying the flagship products in the field of APIs, animal and plant extracts, including Ursodeoxycholic Acid, Hesperidin, Diosmin and a variety of oncology APIs. Relying on 100,000-class clean workshops and FDA/EU GMP/Japanese GMP certification systems, Xieli Pharmaceutical's strong technical strength attracted intensive consultations from customers in Southeast Asia and South Asia, demonstrating the R&D advantages of a "national high-tech enterprise".

Striving in Three Dimensions, Deepening New Impetus for Regional Cooperation

1. Deepen the Layout in the Southeast Asian Market

As one of the fastest-growing regions in the global pharmaceutical market, Southeast Asia has always been a core part of Xieli Pharma internationalization strategy. During the exhibition, taking the opportunity of CPHI Southeast Asia, Xieli Pharma held one-on-one talks with pharmaceutical enterprises and distributors from Malaysia, Vietnam, Indonesia and other countries to discuss local cooperation models, helping the company's products enter the regional market more efficiently.

2. Strengthen Supply Chain Collaboration

In response to Southeast Asian customers' most concerned issues of supply chain stability and quality compliance, Xieli team demonstrated on-site the company's GMP management system, international certification and other service capabilities, which effectively dispelled the concerns of partners and further enhanced their confidence.

3. Explore Innovative Cooperation Opportunities

During the exhibition, in addition to traditional API cooperation, the company also discussed the possibility of cooperation in multiple fields with Southeast Asian enterprises, which not only opened up new scenarios for our products but also laid the foundation for subsequent market expansion.

CPHI Series Exhibitions: Xieli's Path to International Advancement

Xieli Pharma has always adhered to the "technology+internationalization" dual-drive strategy, regarding international exhibitions as a "window for technical exchanges" and a "bridge for cooperation docking". By continuously participating in CPHI global series exhibitions, the company has successfully established cooperation with dozens of countries and regions such as Russia, Japan, Egypt, Europe, and Southeast Asia, building a global product matrix centered on APIs and plant extracts.

In the future, Xieli will continue to take quality as the cornerstone and cooperation as the link, focus on the development path of "product compliance, market internationalization, and service specialization", deepen its efforts in the Southeast Asian market, and radiate to a broader global territory, making the business card of "Chinese pharmaceutical raw materials" more brilliant on the international stage.